Longboard Pharma Stock Surges Over 50% Pre-market, Gets Retail Attention On $2.6B Buyout Deal From Denmark’s Lundbeck

The acquisition will bolster Lundbeck’s pipeline in neuro-rare diseases with Longboard’s drug candidate to treat rare epilepsies